HC Wainwright Reiterates Buy Rating on Arrowhead Pharma, Keeps $120 Target
HC Wainwright reiterated its Buy rating and $120 price target on Arrowhead Pharma. The target implies 105.6% upside from the October 14 close of $58.37.
HC Wainwright reiterated its Buy rating and $120 price target on Arrowhead Pharma. The target implies 105.6% upside from the October 14 close of $58.37.